Study design
toxicity, ICH, death
DISEASE PROGRESSION
This multicenter, single-arm, open-label, phase 2 basket study evaluated the efficacy and safety of dabrafenib plus trametinib in nine cohorts of patients with Patients received oral dabrafenib (150 mg twice daily) and oral trametinib (2 mg once daily) on a continuous dosing schedule until unacceptable toxicity, disease progression or death. Dose adjustments and interruptions were permitted for patients unable to tolerate the protocol-specified dose until tolerability improved. Data cutoff date for this study was 10 December 2021.For patients who discontinued or withdrew from study treatment, follow-up visits were conducted within 28 days after the last dose, every month for the first 6 months for dermatologic assessments and every 3 months thereafter for survival data.The study was conducted in compliance with ICH Good Clinical Practice guidelines and ethical principles described in the Declaration of Helsinki. The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each participating study center. All patients signed a written informed consent before study-specific procedures. The study is registered in ClinicalTrials.gov as 